Načítá se...
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial lung disease associated with significant morbidity and mortality. Previously, IPF has been managed using immunosuppressive therapy; however, it has been shown that this is associated with increased mortality. In the last 5 years, two dis...
Uloženo v:
| Vydáno v: | Ther Adv Respir Dis |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156214/ https://ncbi.nlm.nih.gov/pubmed/30249169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618800618 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|